Hepatic metastasis is a poor predictive marker for erlotinib in lung adenocarcinoma

Area of Science:

• Oncology
• Pharmacology

Background:

• Lung cancer is a leading cause of cancer death globally, often diagnosed at advanced stages with metastasis.
• Targeted therapies like epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) offer improved efficacy and reduced toxicity over traditional chemotherapy for non-small cell lung cancer (NSCLC).
• Hepatocyte growth factor (HGF)-induced MET activation can lead to resistance to EGFR-TKIs in patients with hepatic metastases.

Purpose of the Study:

• To investigate the impact of hepatic metastases on the efficacy of erlotinib in patients with advanced non-small cell lung cancer (NSCLC).
• To determine if hepatic metastasis is a predictive marker for erlotinib treatment outcomes in lung adenocarcinoma.

Main Methods:

• A retrospective analysis of 164 lung adenocarcinoma patients with known EGFR mutation status treated with erlotinib as second or third-line therapy.
• Comparison of disease control rate (DCR) and progression-free survival (PFS) between patients with and without hepatic metastases.

Main Results:

• The DCR was significantly higher in patients without hepatic metastases (66.1%) compared to those with hepatic metastases (54.5%, p<0.001).
• For EGFR mutation-positive patients, median PFS was significantly longer in the absence of hepatic metastases (9.9 months) versus its presence (7.9 months, p=0.017).

Conclusions:

• Hepatic metastasis appears to be a negative predictive marker for erlotinib treatment in lung adenocarcinoma.
• The presence of liver metastases is associated with poorer treatment outcomes in patients receiving erlotinib.